drug-drug interactions

An Overview of Physiologically-Based Pharmacokinetic Models for Forensic Science

mycolabadmin

This review examines how mathematical models that predict how drugs and chemicals move through the body could be better used in forensic science to help explain cause of death and interpret toxicology evidence. Currently, only a few such models have been specifically developed for forensic purposes, though many exist for common drugs like opioids, cocaine, and alcohol. A major challenge is accounting for how drug concentrations change after death, which can make it harder to determine what the concentration was when the person died.

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common because of new medical treatments that suppress immune function, and some fungi are developing resistance to standard medications. However, exciting new antifungal drugs are in development that work in different ways and may be easier to use. The article discusses how doctors need better ways to identify patients at risk, design better clinical trials, and train more specialists to handle these increasingly complex fungal infections.

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

Past, present and future of antifungals: Advancements in mechanisms of action and resistance

mycolabadmin

Fungal infections are a growing global health threat, especially for people with weakened immune systems, causing millions of deaths annually. Currently available antifungal drugs are limited and increasingly face resistance, making them less effective over time. This special collection of research papers explores new approaches to treating fungal infections, including novel drugs, combination therapies, and alternative treatments to overcome resistance. Scientists and doctors hope these advances will help save more lives by providing better options for treating serious fungal diseases.

Clinical aspects and recent advances in fungal diseases impacting human health

mycolabadmin

Fungal infections affect over a billion people worldwide and are becoming harder to treat due to growing resistance to antifungal medications. The review discusses major challenges in detecting and treating these infections, including difficulty in diagnosis and limited awareness among healthcare providers. New antifungal drugs are being developed and approved to address these challenges, but a comprehensive approach involving better awareness, improved testing, and responsible medication use is needed.

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and dangerous, especially for people with weakened immune systems, and many fungi are developing resistance to current medications. Doctors and researchers are developing new treatment strategies, including combining multiple drugs together and using advanced technologies to deliver medicines more effectively to infected areas. Natural compounds from plants and new biotechnology tools like genetic engineering and nanoparticles show promising results for fighting drug-resistant fungal infections.

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and harder to treat due to drug resistance, especially in people with weakened immune systems. Current antifungal medications are becoming less effective because fungi are adapting to resist them, and these drugs can cause serious side effects. Scientists are developing new treatment strategies using combinations of existing drugs, engineered biological approaches, and specially designed delivery systems to overcome resistance and improve patient outcomes.

Past, present and future of antifungals: Advancements in mechanisms of action and resistance

mycolabadmin

Fungal infections are a growing global health problem, particularly for people with weakened immune systems, causing millions of deaths annually. Current antifungal medications are limited and increasingly ineffective due to drug-resistant fungi. This special issue explores new treatment strategies including novel drugs, combination therapies, and innovative approaches like nanoparticles and antimicrobial peptides to combat these serious infections.

A Case of Superficial Mycoses in a Patient with Systemic Lupus Erythematosus

mycolabadmin

A 52-year-old woman with lupus developed severe fungal skin infections that were initially mistaken for worsening lupus symptoms. Her condition improved after 6 months of treatment with two antifungal medications (terbinafine and itraconazole). This case reminds doctors that patients taking immunosuppressive medications for lupus are at high risk for fungal infections, which can be misdiagnosed as lupus flares.

Antifungal stewardship in the UK: where are we now?

mycolabadmin

This paper examines how well the UK is currently managing antifungal stewardship—the appropriate use of antifungal medications to treat serious fungal infections while preventing resistance. Experts found that since 2017, progress has been limited due to lack of funding and staff expertise, difficulties accessing timely fungal diagnostic tests, and disruptions from the COVID-19 pandemic. The panel recommends creating regional mycology networks and diagnostic centres, establishing national standards for antifungal practices, and improving education about fungal infections to better prepare the UK for rising fungal disease threats.

Anti-Therapeutic Action: drug-drug interactions